4/A//SEC Filing
CR Group L.P. 4/A
Accession 0001209191-23-042307
CIK 0001492674other
Filed
Jul 13, 8:00 PM ET
Accepted
Jul 14, 6:57 PM ET
Size
17.1 KB
Accession
0001209191-23-042307
Insider Transaction Report
Form 4/AAmended
Transactions
- Award
Series B Convertible Preferred Stock
2023-07-03+59,703→ 59,703 total(indirect: By CRG Partners III Parallel Fund (B) (Cayman) L.P.)Exercise: $0.07→ Common Stock (59,703,000 underlying) - Award
Series B Convertible Preferred Stock
2023-07-03+33,595→ 33,595 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)Exercise: $0.07→ Common Stock (33,595,000 underlying)
Transactions
- Award
Series B Convertible Preferred Stock
2023-07-03+59,703→ 59,703 total(indirect: By CRG Partners III Parallel Fund (B) (Cayman) L.P.)Exercise: $0.07→ Common Stock (59,703,000 underlying) - Award
Series B Convertible Preferred Stock
2023-07-03+33,595→ 33,595 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)Exercise: $0.07→ Common Stock (33,595,000 underlying)
Capital Royalty L.P.
10% Owner
Transactions
- Award
Series B Convertible Preferred Stock
2023-07-03+33,595→ 33,595 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)Exercise: $0.07→ Common Stock (33,595,000 underlying) - Award
Series B Convertible Preferred Stock
2023-07-03+59,703→ 59,703 total(indirect: By CRG Partners III Parallel Fund (B) (Cayman) L.P.)Exercise: $0.07→ Common Stock (59,703,000 underlying)
CRG Partners III L.P.
10% Owner
Transactions
- Award
Series B Convertible Preferred Stock
2023-07-03+33,595→ 33,595 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)Exercise: $0.07→ Common Stock (33,595,000 underlying) - Award
Series B Convertible Preferred Stock
2023-07-03+59,703→ 59,703 total(indirect: By CRG Partners III Parallel Fund (B) (Cayman) L.P.)Exercise: $0.07→ Common Stock (59,703,000 underlying)
Transactions
- Award
Series B Convertible Preferred Stock
2023-07-03+33,595→ 33,595 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)Exercise: $0.07→ Common Stock (33,595,000 underlying) - Award
Series B Convertible Preferred Stock
2023-07-03+59,703→ 59,703 total(indirect: By CRG Partners III Parallel Fund (B) (Cayman) L.P.)Exercise: $0.07→ Common Stock (59,703,000 underlying)
Transactions
- Award
Series B Convertible Preferred Stock
2023-07-03+59,703→ 59,703 total(indirect: By CRG Partners III Parallel Fund (B) (Cayman) L.P.)Exercise: $0.07→ Common Stock (59,703,000 underlying) - Award
Series B Convertible Preferred Stock
2023-07-03+33,595→ 33,595 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)Exercise: $0.07→ Common Stock (33,595,000 underlying)
Footnotes (3)
- [F1]The acquisition of these shares was inadvertently omitted from the reporting persons' Form 4 filed with the SEC on July 6, 2023.
- [F2]Each share of Series B Convertible Preferred Stock (the "Series B Preferred") converts into 1,000 shares of the Company's common stock at the holder's election, subject to beneficial ownership limitations, including that a holder of Series B Preferred is prohibited from converting such shares into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. As a result of the 19.99% beneficial ownership limitation, as of July 3, 2023, the Series B Preferred held by the reporting persons can be converted into a maximum of 24,157,794 shares of common stock in the aggregate. The shares of Series B Preferred have no expiration date.
- [F3]Pursuant to that certain Securities Purchase Agreement, dated July 3, 2023, by and among the Company, CRG Partners III L.P., CRG Partners III - Parallel Fund "A" L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund "B" (Cayman) L.P. (collectively, the "CRG Entities"), the CRG Entities received these shares in exchange for the CRG Entities surrendering for cancellation of certain outstanding debt.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001702352
Filing Metadata
- Form type
- 4/A
- Filed
- Jul 13, 8:00 PM ET
- Accepted
- Jul 14, 6:57 PM ET
- Size
- 17.1 KB